MUC16 and neoplasm: Pre-treatment with both parental antibodies resulted in the total lack of biodistribution of the 89Zr-labeled MUC16xCD3M bsAb, whereas pre-treatment with parental CD3 antibody resulted in distribution to the tumor site, due to recognition of MUC16 on tumor cells (Fig. 6b).